EOM Pharmaceuticals Holdings, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IMUC research report →
Price Chart
About the company
EOM Pharmaceuticals Holdings, Inc. , a clinical-stage biotechnology company, focuses on the development of drugs to transform therapeutic paradigms and enhance quality of life in patients suffering from debilitating and deadly diseases in the United States. The company’s lead compound is EOM613, a peptide nucleic-acid solution with both anti-inflammatory and pro-inflammatory broad spectrum cytokine effects that has completed Phase 2 clinical trials for the treatment of cancer cachexia, AIDS/cancer cachexia, HIV/AIDS, and rheumatoid arthritis, as well as in Phase ½ a clinical trial to treat infectious diseases, such as COVID-19.
- CEO
- Irach Taraporewala
- IPO
- 2021
- Employees
- 3
- HQ
- Montvale, NJ, US
Get TickerSpark's AI analysis on IMUC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $21.25M
- P/E
- -11.05
- PEG
- -0.08
- P/S
- 0.00
- P/B
- -8.88
- EV/EBITDA
- -12.57
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 127.66%
- ROIC
- 287.57%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-1,827,547
- Net Income
- $-1,922,557-1.6%
- EPS
- $-0.02+7.3%
- OCF Growth
- +44.2%
- FCF Growth
- +44.2%
- 52W High
- $0.34
- 52W Low
- $0.02
- 50D MA
- $0.18
- 200D MA
- $0.16
- Beta
- 0.17
- RSI (14)
- 51
- Avg Volume
- 2.18K
No earnings-call transcripts are available for IMUC yet.
- Free Float
- 99.7%
- Shares Outstanding
- 126.50M
- Float Shares
- 126.14M
of shares held by institutions
13 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Virtu Kcg Holdings LLC | 14.16K | ▲ 14.16K |
| Blackrock Fund Advisors | 672 | ▲ 672 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 6, 18 | Yu John S | other | 120,000 |
| Dec 31, 16 | Gengos Andrew | other | 3,284 |
| Jun 17, 16 | Yu John S | other | 156,750 |
| Jun 17, 16 | Titus Gary | other | 156,750 |
| Jun 17, 16 | Singhvi Rahul | other | 156,750 |
| Jun 17, 16 | SCHLOSSBERG MARK A | other | 156,750 |
| Jun 17, 16 | LAPOINTE ANTHONY GREGG | other | 156,750 |
| Mar 11, 16 | Swanson Steven J | other | 150,000 |
| Mar 11, 16 | Swanson Steven J | other | 25,000 |
| Mar 11, 16 | FRACTOR DAVID | other | 100,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our IMUC coverage
Recent articles, reports, and earnings notes.
No research on IMUC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IMUC report →EOM Pharmaceutical (OTCMKTS:IMUC) & Siga Technologies (NASDAQ:SIGA) Financial Survey
defenseworld.net · Mar 21
EOM Pharmaceutical (OTCMKTS:IMUC) Trading 139% Higher – Still a Buy?
defenseworld.net · Dec 30
EOM Pharmaceutical Holdings Provides an Update on its Lead Drug Candidate EOM613
prnewswire.com · Nov 7
EOM Pharmaceutical Holdings Announces Topline Results of its COVID-19 Clinical Trial of EOM613 in Brazil
prnewswire.com · Sep 6
ImmunoCellular Therapeutics Announces Application for Continued Public Quoting on the Over-the-Counter (OTC) Market
prnewswire.com · Jun 28
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.